A Small Molecule Primes Embryonic Stem Cells for Differentiation

The Skaggs Institute of Chemical Biology and the Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Cell stem cell (Impact Factor: 22.15). 06/2009; 4(5):416-26. DOI: 10.1016/j.stem.2009.04.001
Source: PubMed

ABSTRACT Embryonic stem cells (ESCs) are an attractive source of cells for disease modeling in vitro and may eventually provide access to cells/tissues for the treatment of many degenerative diseases. However, applications of ESC-derived cell types are largely hindered by the lack of highly efficient methods for lineage-specific differentiation. Using a high-content screen, we have identified a small molecule, named stauprimide, that increases the efficiency of the directed differentiation of mouse and human ESCs in synergy with defined extracellular signaling cues. Affinity-based methods revealed that stauprimide interacts with NME2 and inhibits its nuclear localization. This, in turn, leads to downregulation of c-Myc, a key regulator of the pluripotent state. Thus, our findings identify a chemical tool that primes ESCs for efficient differentiation through a mechanism that affects c-Myc expression, and this study points to an important role for NME2 in ESC self-renewal.

Download full-text


Available from: Costas A Lyssiotis, Aug 26, 2015
  • Source
    • "Advances in chemistry have returned unparalleled sensitivity and scope for detecting, isolating and identifying not only the major metabolites (as was the norm only two decades ago), but the full array of structurally related minor cometabolites – Nature " s equivalent of combinatorial chemistry (Chen et al., 2009). Empowered by ready access to such pre-programmed bioactive chemical diversity, structure activity relationship (SAR) investigations by co-metabolite have become a powerful paradigm for accelerating the evaluation and characterization of new drug classes (pharmacophores) (Zhan et al., 2008).More recently the differentiation of embryonic stem cells for disease modeling in-vitro by using "Stauprimide" a family of indolecarbazoles from Streptomyces staurosporeus (Zhu et al., 2009). A new group of obligate marine actinomycete produced "Salinosporamide-A" shows cytotoxic towards HCT-116 human colon carcinoma cell lines (Feeling et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: o maintain and improve the quality of life offered by modern healthcare requires an ongoing commitment to the development of new drugs, to improve and replace those that have become less effective, and to bring to the community safer treatments for an ever-wider array of important diseases. Irrespective of the specific medical need, the drug discovery pipeline is critically dependent on access to diverse, high-quality molecular libraries capable of inspiring drug-led discovery, and ultimately new drugs. A poor choice of chemistry leads to wasted resources and no drugs. Historically the pharmaceutical industry has relied heavily on microbial natural products, which represent an extraordinarily diverse, preassembled pool of biologically active molecules, programmed to be potent and selective modulators of key biopolymers, cells, tissues, organs and animals. Knowledge of Nature’s intellectual property, gleaned from the evolutionary equivalent of a billion-year global drug discovery program, with an unlimited budget and a workforce of trillions, can disclose privileged bioactive structures that inform, guide and inspire modern drug discovery, re-purposing ecological advantage to pharmaceutical benefit. Although we cannot see them, microbes are essential for every part of human life; indeed all life on Earth. The emerging field of metagenomics provides a new way of viewing the microbial world that will not only transform modern microbiology, but also may revolutionize understanding of the entire living world.
  • Source
    • "Author's personal copy resulting in downregulation of c-Myc, a key factor in the maintenance of ESC self-renewal (Zhu et al., 2009). Thus, Spd is dependent on the subsequent treatment with Activin A for the differentiation of Spd-primed ESC to definitive endoderm. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is a group of metabolic diseases, rising globally at an alarming rate. Type 1 (juvenile diabetes) is the autoimmune version of diabetes where the pancreas is unable to produce insulin, whereas Type 2 (adult onset diabetes) is caused due to insulin resistance of the cells. In either of the cases, elevated blood glucose levels are observed which leads to progressive comorbidity like renal failure, cardiovascular disease, retinopathy, etc. Metformin, sulphonyl urea group of drugs, as well as insulin injections are the available therapies. In advanced cases of diabetes, the drug alone or drug in combination with insulin injections are not able to maintain a steady level of blood glucose. Moreover, frequent insulin injections are rather cumbersome for the patient. So, regenerative medicine could be a permanent solution for fighting diabetes. Islet transplantation has been tried with a limited amount of success on a large population of diabetics because of the shortage of cadaveric pancreas. Therefore, the best proposed alternative is regenerative medicine involving human pluripotent stem cell (hPSC)-derived beta islet transplantation which can be obtained in large quantities. Efficient protocols for in vitro differentiation of hPSC into a large number of sustained insulin-producing beta cells for transplantation will be considered to be a giant leap to address global rise in diabetic cases. Although most of the protocols mimic in vivo pancreatic development in humans, considerable amount of lacuna persists for near-perfect differentiation strategies. Moreover, beta islets differentiated from hPSC have not yet been successfully translated under clinical scenario.
    Vitamins & Hormones 01/2014; 95:223-48. DOI:10.1016/B978-0-12-800174-5.00009-0 · 1.78 Impact Factor
  • Source
    • "These results also suggest that it would be important to examine the subcellular localization of NM23-H1 protein overexpressed in leukemia and lymphoma. Zhu et al. have reported an interesting small molecule, named stauprimide, that increases the efficiency of the directed differentiation of mouse and human embryonic stem cells (ESCs) in synergy with defined extracellular signaling cues, such as activin A [70]. Using an affinity-based approach, NM23-H2 was identified as the biological target of stauprimide. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An elevated serum level of NM23-H1 protein is a poor prognostic factor in patients with various hematologic malignancies. The extracellular NM23-H1 protein promotes the in vitro growth and survival of acute myelogenous leukemia (AML) cells and inversely inhibits the in vitro survival of normal peripheral blood monocytes in primary culture at concentrations equivalent to the levels found in the serum of AML patients. The growth and survival promoting activity to AML cells is associated with cytokine production and activation of mitogen-activated protein kinases (MAPKs) and signal transducers and activators of transcription (STAT) signaling pathways. Inhibitors specific for MAPK signaling pathways inhibit the growth/survival-promoting activity of NM23-H1. These findings indicate a novel biological action of extracellular NM23-H1 and its association with poor prognosis. These results suggest an important role of extracellular NM23-H1 in the malignant progression of leukemia and a potential therapeutic target for these malignancies.
    Advances in Hematology 01/2012; 2012(1687-9104):879368. DOI:10.1155/2012/879368
Show more